{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:13:16Z","timestamp":1789708396428,"version":"4.0.1"},"reference-count":431,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In 2024, the Food and Drug Administration approved 47 new molecular entities (NMEs), including 15 therapeutic antibody-based molecules, marking the 30th anniversary of the first approved recombinant antibody. Ten of these were recombinant immunoglobulin G antibodies, while the rest comprised three bispecific antibodies, one immunocytokine, and one Fc-fusion protein. Seven antibodies targeted previously approved targets like programmed cell death receptor-1, programmed cell death receptor ligand-1, complement factor C5, interleukin (IL)-13, human epidermal growth factor receptor 2 (HER2) (biparatopic), and a novel form of amyloid-beta for conditions like esophageal squamous cell carcinoma, cutaneous squamous cell carcinoma, paroxysmal nocturnal hemoglobinuria, atopic dermatitis, biliary tract cancer, and Alzheimer\u2019s disease, respectively. The other seven recognized novel targets such as activin for pulmonary arterial hypertension, IL-15R\u03b2\u03b3 agonist for bladder cancer, delta-like ligand-3 \u00d7 cluster of differentiation-3 for small cell lung cancer (SCLC), IL-31 receptor for prurigo nodularis, colony stimulating factor-1 receptor for graft-versus-host disease, tissue factor pathway inhibitor for Hemophilia A and B, and claudin 18.2 for gastric or gastroesophageal junction cancers. Additionally, a HER2\u2013HER3 bispecific antibody was approved for non-SCLC and pancreatic adenocarcinoma. Three reformulated antibodies with hyaluronidase HP20 for subcutaneous administration were also approved, although not as New Molecular Entities (NME)s.<\/jats:p>","DOI":"10.1093\/abt\/tbaf014","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T08:00:35Z","timestamp":1751011235000},"page":"197-237","source":"Crossref","is-referenced-by-count":16,"title":["Structure and function of therapeutic antibodies approved by the US FDA in 2024"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8271-6875","authenticated-orcid":false,"given":"William R","family":"Strohl","sequence":"first","affiliation":[{"name":"BiStro Biotechnology Consulting , 1086 Tullo Farm Rd., Bridgewater, NJ 08807 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"2026050905022527100_ref1","author":"Strohl"},{"key":"2026050905022527100_ref2","volume-title":"FDA Revokes EUAs of Four COVID-19 Monoclonal Antibodies","author":"Ingram"},{"key":"2026050905022527100_ref3","volume-title":"FDA Authorizes COVID Drug Pemgarda for High-Risk Patients","author":"MacMillan"},{"key":"2026050905022527100_ref4","volume-title":"Novel Drug Approvals for 2024"},{"key":"2026050905022527100_ref5","volume-title":"Advancing Health through Innovation: New Drug Therapy Approvals 2024"},{"key":"2026050905022527100_ref6","volume-title":"2024 Biological License Application Approvals"},{"key":"2026050905022527100_ref7","doi-asserted-by":"publisher","first-page":"2297450","DOI":"10.1080\/19420862.2023.2297450","article-title":"Antibodies to watch in 2024","volume":"16","author":"Crescioli","year":"2024","journal-title":"MAbs"},{"key":"2026050905022527100_ref8","doi-asserted-by":"publisher","first-page":"2443538","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"Crescioli","year":"2025","journal-title":"MAbs"},{"key":"2026050905022527100_ref9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/abt\/tbae007","article-title":"Structure and function of therapeutic antibodies approved by the US FDA in 2023","volume":"7","author":"Strohl","year":"2024","journal-title":"Antib Ther"},{"key":"2026050905022527100_ref10","first-page":"37","volume-title":"2013 Sales of Recombinant Therapeutic Antibodies & Proteins"},{"key":"2026050905022527100_ref11","first-page":"39","volume-title":"2014 Sales of Recombinant Therapeutic Antibodies & Proteins"},{"key":"2026050905022527100_ref12","first-page":"39","volume-title":"2015 Sales of Recombinant Therapeutic Antibodies & Proteins"},{"key":"2026050905022527100_ref13","first-page":"39","volume-title":"2016 Sales of Recombinant Therapeutic Antibodies & Proteins"},{"key":"2026050905022527100_ref14","first-page":"53","volume-title":"2017 Sales of Recombinant Therapeutic Antibodies & Proteins"},{"key":"2026050905022527100_ref15","first-page":"55","volume-title":"2018 Sales of Recombinant Therapeutic Antibodies & Proteins"},{"key":"2026050905022527100_ref16","first-page":"65","volume-title":"2019 Sales of Recombinant Therapeutic Antibodies & Proteins"},{"key":"2026050905022527100_ref17","first-page":"88","volume-title":"2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics"},{"key":"2026050905022527100_ref18","first-page":"66","volume-title":"2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics"},{"key":"2026050905022527100_ref19","first-page":"71","volume-title":"2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics"},{"key":"2026050905022527100_ref20","first-page":"77","volume-title":"2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics"},{"key":"2026050905022527100_ref21","first-page":"84","volume-title":"2024 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics"},{"key":"2026050905022527100_ref22","volume-title":"Global Antibody Market 2024 to 2034 Growing at a CAGR of 8.1%, the Global Market to Reach USD 581.42 Billion by 2034"},{"key":"2026050905022527100_ref23","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.21037\/tlcr-23-115","article-title":"Tarlatamab: the promising immunotherapy on its way from the lab to the clinic","volume":"12","author":"Tang","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"2026050905022527100_ref24","doi-asserted-by":"publisher","first-page":"P201","DOI":"10.1158\/1535-7163.TARG-21-P201","volume-title":"AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics","author":"Gerlach"},{"key":"2026050905022527100_ref25","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1158\/1538-7445.AM2021-1005","article-title":"Abstract 1005: the bispecific antibody zanidatamab\u2019s (ZW25\u2019s) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers","volume":"81","author":"Weisser","year":"2021","journal-title":"Cancer Res"},{"key":"2026050905022527100_ref83","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40256-024-00694-w","article-title":"Sotatercept: The first FDA-approved activin a receptor IIA inhibitor used in the management of pulmonary arterial hypertension","volume":"25","author":"Villanueva","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026050905022527100_ref84","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40265-024-02060-1","article-title":"Nogapendekin alfa Inbakicept: First approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs."},{"key":"2026050905022527100_ref80","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","article-title":"AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer","volume":"27","author":"Giffin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026050905022527100_ref85","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","article-title":"Tarlatamab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs."},{"key":"2026050905022527100_ref86","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40265-024-02056-x","article-title":"Zolbetuximab: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs."},{"key":"2026050905022527100_ref87","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","article-title":"Claudin 18.2 as a novel therapeutic target","volume":"21","author":"Nakayama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026050905022527100_ref88","doi-asserted-by":"publisher","first-page":"CD014544","DOI":"10.1002\/14651858.CD014544.pub2","article-title":"Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B","volume":"2024","author":"Olasupo","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2026050905022527100_ref26","first-page":"174","volume-title":"WHO Drug Info","author":"Tislelizumabum","year":"2018"},{"key":"2026050905022527100_ref27","author":"Tevimbra\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref28","volume-title":"TEVIMBRA\u00ae Approved in U.S. for First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy","year":"2024"},{"key":"2026050905022527100_ref29","first-page":"97","volume-title":"WHO Drug Info","author":"Sotaterceptum","year":"2011"},{"key":"2026050905022527100_ref30","author":"Winrevair\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref31","year":"2024"},{"key":"2026050905022527100_ref32","first-page":"61","volume-title":"WHO Drug Info","author":"Nogapendekinum alfa","year":"2020"},{"key":"2026050905022527100_ref33","first-page":"644","volume-title":"WHO Drug Info","author":"Inbakicept-pmln","year":"2019"},{"key":"2026050905022527100_ref34","author":"Anktiva\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref35","year":"2024"},{"key":"2026050905022527100_ref36","first-page":"214","volume-title":"WHO Drug Info","author":"Tarlatamabum","year":"2021"},{"key":"2026050905022527100_ref37","author":"Imdelltra\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref38","volume-title":"FDA Approves IMDELLTRA\u2122 (Tarlatamab-Dlle), the First and Only T-Cell Engager Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer","year":"2024"},{"key":"2026050905022527100_ref39","first-page":"61","volume-title":"WHO Drug Info","author":"Crovalimabum","year":"2019"},{"key":"2026050905022527100_ref40","author":"Piasky\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref41","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41598-017-01087-7","article-title":"Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases","volume":"7","author":"Fukuzawa","year":"2017","journal-title":"Sci Rep"},{"key":"2026050905022527100_ref42","year":"2024"},{"key":"2026050905022527100_ref43","first-page":"629","volume-title":"WHO Drug Info","author":"Donanemabum","year":"2019"},{"key":"2026050905022527100_ref44","author":"Kisunla\u00ae prescribing information","year":"2024"},{"key":"2026050905022527100_ref45","year":"2024"},{"key":"2026050905022527100_ref48"},{"key":"2026050905022527100_ref46","first-page":"411","volume-title":"WHO Drug Info","author":"Nemolizumabum","year":"2015"},{"key":"2026050905022527100_ref47","author":"Nemluvio\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref49","volume-title":"FDA Approval for Nemluvio\u00ae (Nemolizumab) for Adult Patients Living with Prurigo Nodularis","author":"Galderma receives U.S","year":"2024"},{"key":"2026050905022527100_ref50","first-page":"12","volume-title":"WHO Drug Info","author":"Axatilimabum","year":"2020"},{"key":"2026050905022527100_ref51","author":"Niktimvo\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref52","year":"2024"},{"key":"2026050905022527100_ref53","first-page":"63","volume-title":"WHO Drug Info","author":"Lebrikizumabum","year":"2010"},{"key":"2026050905022527100_ref54","author":"Ebglyss\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref55","year":"2024"},{"key":"2026050905022527100_ref56","first-page":"83","volume-title":"WHO Drug Info","author":"Marstacimabum","year":"2019"},{"key":"2026050905022527100_ref57","author":"Hympavzi\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref58","year":"2024"},{"key":"2026050905022527100_ref59","first-page":"182","volume-title":"WHO Drug Info","author":"Zolbetuximabum","year":"2018"},{"key":"2026050905022527100_ref60","author":"Vyloy\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref61","year":"2024"},{"key":"2026050905022527100_ref62","first-page":"112","volume-title":"WHO Drug Info","author":"Zanidatamabum","year":"2020"},{"key":"2026050905022527100_ref63","author":"Ziihera\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref64","year":"2024"},{"key":"2026050905022527100_ref65","first-page":"p174","volume-title":"WHO Drug Info","author":"Zenocutuzumabum","year":"2018"},{"key":"2026050905022527100_ref66","author":"Bizengri\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref67","year":"2024"},{"key":"2026050905022527100_ref68","first-page":"22","volume-title":"WHO Drug Info","author":"Cosibelimabum","year":"2020"},{"key":"2026050905022527100_ref69","author":"Unloxcyt\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref70","year":"2024"},{"key":"2026050905022527100_ref71","first-page":"282","volume-title":"WHO Drug Info","author":"Concizumabum","year":"2013"},{"key":"2026050905022527100_ref72","author":"Alhemo\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref73","year":"2024"},{"key":"2026050905022527100_ref74","first-page":"180","volume-title":"WHO Drug Info","author":"Obecabtagene autoleucel","year":"2023"},{"key":"2026050905022527100_ref75","author":"Aucatzyl\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref76","year":"2024"},{"key":"2026050905022527100_ref77","author":"Dunleavy","year":"2024"},{"key":"2026050905022527100_ref89","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0161-5890(93)90432-b","article-title":"A single amino acid substitution abolishes the heterogeneity of chimeric mouse\/human (IgG4) antibody","volume":"30","author":"Angal","year":"1993","journal-title":"Mol Immunol"},{"key":"2026050905022527100_ref90","doi-asserted-by":"publisher","first-page":"1779974","DOI":"10.1080\/19420862.2020.1779974","article-title":"Prevention of Fab-arm exchange and antibody reduction via stabilization of the IgG4 hinge region","volume":"12","author":"Handlogten","year":"2020","journal-title":"MAbs"},{"key":"2026050905022527100_ref91","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1002\/jps.24620","article-title":"Comprehensive analysis of the therapeutic IgG4 antibody pembrolizumab: hinge modification blocks half molecule exchange in vitro and in vivo","volume":"104","author":"Yang","year":"2015","journal-title":"J Pharm Sci"},{"key":"2026050905022527100_ref92","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.copbio.2009.10.011","article-title":"Optimization of Fc-mediated effector functions of monoclonal antibodies","volume":"20","author":"Strohl","year":"2009","journal-title":"Curr Opin Biotechnol"},{"key":"2026050905022527100_ref93","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/imr.13379","article-title":"Living in LALA land? Forty years of attenuating Fc effector functions","volume":"328","author":"Hale","year":"2024","journal-title":"Immunol Rev"},{"key":"2026050905022527100_ref94","doi-asserted-by":"publisher","first-page":"2402701","DOI":"10.1080\/19420862.2024.2402701","article-title":"Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors","volume":"16","author":"Hale","year":"2024","journal-title":"MAbs"},{"key":"2026050905022527100_ref95","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1074\/jbc.M116.748525","article-title":"Engineering an IgG scaffold lacking effector function with optimized developability","volume":"292","author":"Jacobsen","year":"2017","journal-title":"J Biol Chem"},{"key":"2026050905022527100_ref96","doi-asserted-by":"publisher","first-page":"e0260954","DOI":"10.1371\/journal.pone.0260954","article-title":"Fc-engineered antibodies with immune effector functions completely abolished","volume":"16","author":"Wilkinson","year":"2021","journal-title":"PloS One"},{"key":"2026050905022527100_ref78","first-page":"586","article-title":"Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss","volume":"12","author":"Raje","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"2026050905022527100_ref79","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.cyto.2011.09.028","article-title":"IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization","volume":"56","author":"Han","year":"2011","journal-title":"Cytokine"},{"key":"2026050905022527100_ref81","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s10637-018-0593-x","article-title":"Translational PK-PD modeling analysis of MCLA-128, a HER2\/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose","volume":"36","author":"Vries Schultink","year":"2018","journal-title":"Invest New Drugs"},{"key":"2026050905022527100_ref82","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1200\/JCO.21.00917","article-title":"Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"39","author":"Roddie","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026050905022527100_ref104","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1358\/dot.2015.51.4.2291051","article-title":"Blinatumomab for the treatment of adult acute lymphoblastic leukemia","volume":"51","author":"Dahl","year":"2015","journal-title":"Drugs Today (Barc)"},{"key":"2026050905022527100_ref105","doi-asserted-by":"publisher","first-page":"e57479","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PloS One"},{"key":"2026050905022527100_ref106","doi-asserted-by":"publisher","first-page":"100641","DOI":"10.1016\/j.jbc.2021.100641","article-title":"Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET","volume":"296","author":"Neijssen","year":"2021","journal-title":"J Biol Chem"},{"key":"2026050905022527100_ref107","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, a TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026050905022527100_ref108","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology."},{"key":"2026050905022527100_ref109","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv"},{"key":"2026050905022527100_ref110","doi-asserted-by":"publisher","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026050905022527100_ref111","doi-asserted-by":"publisher","first-page":"102625","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody - CD3 x CD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine."},{"key":"2026050905022527100_ref112","doi-asserted-by":"publisher","first-page":"e0241091","DOI":"10.1371\/journal.pone.0241091","article-title":"Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFN\u03b3\/CXCL10-dependent peripheral T cell recruitment in humanized murine model","volume":"16","author":"Cremasco","year":"2021","journal-title":"PloS One"},{"key":"2026050905022527100_ref113","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D \u00d7 CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood."},{"key":"2026050905022527100_ref114","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14737140.2023.2236303","article-title":"Elranatamab: a new promising BispAb in multiple myeloma treatment","volume":"23","author":"Grosicki","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"2026050905022527100_ref115","first-page":"560","article-title":"Preclinical activity of MCLA-128, an ADCC enhanced bispecific IgG1 antibody targeting the HER2:HER3 heterodimer","volume":"32","author":"Geuijen","year":"2014","journal-title":"ASCO Ann Meet"},{"key":"2026050905022527100_ref116","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1073\/pnas.63.1.78","article-title":"The covalent structure of an entire gammaG immunoglobulin molecule","volume":"63","author":"Edelman","year":"1969","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026050905022527100_ref117","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nbt0798-677","article-title":"An efficient route to human bispecific IgG","volume":"16","author":"Merchant","year":"1998","journal-title":"Nat Biotechnol"},{"key":"2026050905022527100_ref97","doi-asserted-by":"publisher","first-page":"2153410","DOI":"10.1080\/19420862.2022.2153410","article-title":"Antibodies to watch in 2023","volume":"15","author":"Kaplon","year":"2023","journal-title":"MAbs."},{"key":"2026050905022527100_ref98","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2026050905022527100_ref99","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40259-024-00691-0","article-title":"The evolving applications of bispecific antibodies: reaping the harvest of early sowing and planting new seeds","volume":"39","author":"Ellerman","year":"2025","journal-title":"BioDrugs."},{"key":"2026050905022527100_ref100","doi-asserted-by":"publisher","first-page":"103267","DOI":"10.1016\/j.copbio.2025.103267","article-title":"Matchmaking at the cell surface using bispecifics to put cells on their best behavior","volume":"92","author":"Driscoll","year":"2025","journal-title":"Curr Opin Biotechnol"},{"key":"2026050905022527100_ref101","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"2026050905022527100_ref102","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.chembiol.2024.07.004","article-title":"Therapeutic potential of cis-targeting bispecific antibodies","volume":"31","author":"Oslund","year":"2024","journal-title":"Cell Chem Biol"},{"key":"2026050905022527100_ref103","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026050905022527100_ref118","author":"Seymore"},{"key":"2026050905022527100_ref119","year":"2019"},{"key":"2026050905022527100_ref128","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","article-title":"Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1\/PD-L2","volume":"25","author":"Zak","year":"2017","journal-title":"Structure."},{"key":"2026050905022527100_ref129","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/cr.2016.77","article-title":"Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab","volume":"27","author":"Na","year":"2017","journal-title":"Cell Res"},{"key":"2026050905022527100_ref130","doi-asserted-by":"publisher","first-page":"14369","DOI":"10.1038\/ncomms14369","article-title":"An unexpected N-terminal loop in PD-1 dominates binding by nivolumab","volume":"8","author":"Tan","year":"2017","journal-title":"Nat Commun"},{"key":"2026050905022527100_ref131","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.3390\/biomedicines10123154","article-title":"The high-resolution structure reveals remarkable similarity in PD-1 binding of cemiplimab and dostarlimab, the FDA-approved antibodies for cancer immunotherapy","volume":"10","author":"Jeong","year":"2022","journal-title":"Biomedicines."},{"key":"2026050905022527100_ref132","author":"Keytruda\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref133","author":"Opdivo\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref134","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.1038\/s41598-017-06002-8","article-title":"Molecular mechanism of PD-1\/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"2026050905022527100_ref135","author":"Tecentriq\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref136","author":"Bavencio\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref137","author":"Imfinzi\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref138","author":"Libtayo\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref139","author":"Jemperli\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref140","doi-asserted-by":"publisher","first-page":"151106","DOI":"10.1016\/j.bbrc.2024.151106","article-title":"High-resolution crystal structure of PD-1 in complex with retifanlimab, the FDA-approved immune checkpoint blocking antibody for treating Merkel cell carcinoma","volume":"742","author":"Cho","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"key":"2026050905022527100_ref141","author":"Zynyz\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref142","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/19420862.2019.1596513","article-title":"Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy","volume":"11","author":"Liu","year":"2019","journal-title":"MAbs."},{"key":"2026050905022527100_ref143","author":"Loqtorzi\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref144","doi-asserted-by":"publisher","first-page":"10732748221111296","DOI":"10.1177\/10732748221111296","article-title":"Tislelizumab: a modified anti-tumor programmed death receptor 1 antibody","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Control"},{"key":"2026050905022527100_ref145","volume-title":"Preclinical Characterization of a Novel Fully Human IgG1 Anti-PD-L1 mAb CK-301","author":"Gorelik","year":"2016"},{"key":"2026050905022527100_ref120","year":"2021"},{"key":"2026050905022527100_ref121","author":"Masson","year":"2025"},{"key":"2026050905022527100_ref122","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"2026050905022527100_ref123","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"2026050905022527100_ref124","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"2026050905022527100_ref125","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"2026050905022527100_ref126","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown","year":"2003","journal-title":"J Immunol"},{"key":"2026050905022527100_ref127","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","article-title":"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy","volume":"54","author":"Blank","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"2026050905022527100_ref146","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"2026050905022527100_ref147","author":"Veverka","year":"2013"},{"key":"2026050905022527100_ref148","author":"Heo","year":"2017"},{"key":"2026050905022527100_ref150","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","article-title":"The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: New estimates from GLOBOCAN 2020","volume":"163","author":"Morgan","year":"2022","journal-title":"Gastroenterology."},{"key":"2026050905022527100_ref151","doi-asserted-by":"publisher","first-page":"100789","DOI":"10.1016\/j.esmoop.2023.100789","article-title":"How we treat esophageal squamous cell carcinoma","volume":"8","author":"Puhr","year":"2023","journal-title":"ESMO Open"},{"key":"2026050905022527100_ref152","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1200\/JCO.22.01490","article-title":"Clinical benefit of first-line programmed death-1 antibody plus chemotherapy in low programmed cell death ligand 1-expressing esophageal squamous cell carcinoma: a post hoc analysis of JUPITER-06 and meta-analysis","volume":"41","author":"Wu","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026050905022527100_ref153","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2026050905022527100_ref154","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","article-title":"Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 Axis","volume":"28","author":"Dahan","year":"2015","journal-title":"Cancer Cell"},{"key":"2026050905022527100_ref155","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3389\/fimmu.2019.00292","article-title":"Fc\u03b3R-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"2026050905022527100_ref156","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/2211-5463.13102","article-title":"Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage","volume":"11","author":"Hong","year":"2021","journal-title":"FEBS Open Bio"},{"key":"2026050905022527100_ref157","doi-asserted-by":"publisher","first-page":"2088454","DOI":"10.1080\/19420862.2022.2088454","article-title":"An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy","volume":"14","author":"Cowles","year":"2022","journal-title":"MAbs"},{"key":"2026050905022527100_ref158","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","article-title":"Tislelizumab: First approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs."},{"key":"2026050905022527100_ref159"},{"key":"2026050905022527100_ref160","volume-title":"A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma","author":"NCT03430843"},{"key":"2026050905022527100_ref161","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.21.01926","article-title":"Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study","volume":"40","author":"Shen","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026050905022527100_ref162","volume-title":"FDA Approves Tislelizumab\/Chemo in Gastric\/GEJ Adenocarcinoma","author":"Fabbricatore","year":"2024"},{"key":"2026050905022527100_ref163","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ."},{"key":"2026050905022527100_ref164","doi-asserted-by":"publisher","first-page":"1523169","DOI":"10.3389\/fonc.2025.1523169","article-title":"Global, regional, national prevalence, mortality, and disability-adjusted life-years of cutaneous squamous cell carcinoma and trend analysis from 1990 to 2021 and prediction to 2045","volume":"15","author":"Liu","year":"2025","journal-title":"Front Oncol"},{"key":"2026050905022527100_ref165"},{"key":"2026050905022527100_ref166","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/14712598.2017.1294156","article-title":"Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity","volume":"17","author":"Hamilton","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"2026050905022527100_ref167","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/imr.13427","article-title":"Fc effector function of immune checkpoint blocking antibodies in oncology","volume":"328","author":"Martineau","year":"2024","journal-title":"Immunol Rev"},{"key":"2026050905022527100_ref168","doi-asserted-by":"publisher","first-page":"e007637","DOI":"10.1136\/jitc-2023-007637","article-title":"Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma","volume":"11","author":"Clingan","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026050905022527100_ref169","doi-asserted-by":"publisher","first-page":"a022053","DOI":"10.1101\/cshperspect.a022053","article-title":"Signaling receptors for TGF-\u03b2 family members","volume":"8","author":"Heldin","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2026050905022527100_ref170","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41422-023-00918-9","article-title":"The roles and regulatory mechanisms of TGF-\u03b2 and BMP signaling in bone and cartilage development, homeostasis and disease","volume":"34","author":"Wu","year":"2024","journal-title":"Cell Res"},{"key":"2026050905022527100_ref171","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cytogfr.2020.09.003","article-title":"Receptor binding competition: a paradigm for regulating TGF-\u03b2 family action","volume":"57","author":"Martinez-Hackert","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"2026050905022527100_ref172","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/s1359-6101(01)00010-7","article-title":"The role of the activin-follistatin system in the developmental and regeneration processes of the kidney","volume":"12","author":"Maeshima","year":"2001","journal-title":"Cytokine Growth Factor Rev"},{"key":"2026050905022527100_ref173","doi-asserted-by":"publisher","first-page":"e68117","DOI":"10.7759\/cureus.68117","article-title":"New and emerging therapeutic drugs for the treatment of pulmonary arterial hypertension: a systematic review","volume":"16","author":"Rasheed","year":"2024","journal-title":"Cureus"},{"key":"2026050905022527100_ref174","doi-asserted-by":"publisher","first-page":"2401324","DOI":"10.1183\/13993003.01324-2024","article-title":"Definition, classification and diagnosis of pulmonary hypertension","volume":"64","author":"Kovacs","year":"2024","journal-title":"Eur Respir J"},{"key":"2026050905022527100_ref175","doi-asserted-by":"publisher","first-page":"87551225251317957","DOI":"10.1177\/87551225251317957","article-title":"Sotatercept: a first-In-class activin signaling inhibitor for pulmonary arterial hypertension","volume":"22","author":"Miranda","year":"2025","journal-title":"J Pharm Technol"},{"key":"2026050905022527100_ref176","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.1182\/blood.V112.11.3866.3866","article-title":"ACE-011, a soluble activin receptor type IIa IgG-Fc fusion protein, increases hemoglobin and hematocrit levels in postmenopausal healthy women","volume":"112","author":"Kim","year":"2008","journal-title":"Blood"},{"key":"2026050905022527100_ref177","doi-asserted-by":"publisher","first-page":"7082","DOI":"10.1073\/pnas.0711263105","article-title":"A soluble activin type IIA receptor induces bone formation and improves skeletal integrity","volume":"105","author":"Pearsall","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026050905022527100_ref178","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/bjh.12838","article-title":"An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin","volume":"165","author":"Carrancio","year":"2014","journal-title":"Br J Haematol"},{"key":"2026050905022527100_ref179","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/jcph.160","article-title":"Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women","volume":"53","author":"Sherman","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"2026050905022527100_ref180","volume-title":"A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) (PULSAR)","author":"NCT03496207"},{"key":"2026050905022527100_ref181","volume-title":"A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003\/\u200bA011\u201311)(STELLAR)","author":"NCT04576988"},{"key":"2026050905022527100_ref182","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.healun.2024.11.037","article-title":"Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: a pooled analysis of PULSAR and STELLAR","volume":"44","author":"Gomberg-Maitland","year":"2025","journal-title":"J Heart Lung Transplant"},{"key":"2026050905022527100_ref183","doi-asserted-by":"publisher","first-page":"2401424","DOI":"10.1183\/13993003.01424-2024","article-title":"Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies","volume":"65","author":"Hoeper","year":"2025","journal-title":"Eur Respir J"},{"key":"2026050905022527100_ref184","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/cpt.3116","article-title":"The impact of immunogenicity on the pharmacokinetics, efficacy, and safety of sotatercept in a phase III study of pulmonary arterial hypertension","volume":"115","author":"Liao","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"2026050905022527100_ref185","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.3390\/cancers12123586","article-title":"Immunomodulatory effects of IL-2 and IL-15; implications for cancer immunotherapy","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026050905022527100_ref186","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ni.2449","article-title":"Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15","volume":"13","author":"Ring","year":"2012","journal-title":"Nat Immunol"},{"key":"2026050905022527100_ref187","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/ni.2472","article-title":"IL-2 and IL-15 signaling complexes: different but the same","volume":"13","author":"Ikemizu","year":"2012","journal-title":"Nat Immunol"},{"key":"2026050905022527100_ref188","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1126\/science.1117893","article-title":"Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gamma receptors","volume":"310","author":"Wang","year":"2005","journal-title":"Science"},{"key":"2026050905022527100_ref189","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.cyto.2011.09.028","article-title":"IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization","volume":"56","author":"Han","year":"2011","journal-title":"Cytokine"},{"key":"2026050905022527100_ref190","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jmb.2008.07.019","article-title":"The exon-3-encoded domain of IL-15R alpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15R alpha","volume":"382","author":"Bouchaud","year":"2008","journal-title":"J Mol Biol"},{"key":"2026050905022527100_ref192","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00262-016-1910-x","article-title":"Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma","volume":"65","author":"Alva","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"2026050905022527100_ref193","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA."},{"key":"2026050905022527100_ref194","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"2026050905022527100_ref195","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.hoc.2014.02.001","article-title":"Interferon, interleukin-2, and other cytokines","volume":"28","author":"Buchbinder","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026050905022527100_ref196","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1182\/blood-2005-06-2399","article-title":"IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients","volume":"107","author":"Ahmadzadeh","year":"2006","journal-title":"Blood"},{"key":"2026050905022527100_ref197","doi-asserted-by":"publisher","first-page":"eabb9283","DOI":"10.1126\/scitranslmed.abb9283","article-title":"Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species","volume":"12","author":"Karakus","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026050905022527100_ref198","doi-asserted-by":"publisher","first-page":"104539","DOI":"10.1016\/j.ebiom.2023.104539","article-title":"A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases","volume":"90","author":"Raeber","year":"2023","journal-title":"EBioMedicine."},{"key":"2026050905022527100_ref199","doi-asserted-by":"publisher","first-page":"1458145","DOI":"10.3389\/fimmu.2024.1458145","article-title":"Leveraging long-acting IL-15 agonists for intratumoral delivery and enhanced antimetastatic activity","volume":"15","author":"Hangasky","year":"2024","journal-title":"Front Immunol"},{"key":"2026050905022527100_ref200","doi-asserted-by":"publisher","first-page":"1184703","DOI":"10.3389\/fphar.2023.1184703","article-title":"Research progress of interleukin-15 in cancer immunotherapy","volume":"14","author":"Cai","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026050905022527100_ref201","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00262-018-2121-4","article-title":"An IL-15 superagonist\/IL-15R\u03b1 fusion complex protects and rescues NK cell-cytotoxic function from TGF-\u03b21-mediated immunosuppression","volume":"67","author":"Fujii","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2026050905022527100_ref202","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","article-title":"NKTR-214, an engineered cytokine with biased IL-2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models","volume":"22","author":"Charych","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026050905022527100_ref203","article-title":"Trials investigating bempegaldesleukin in combination with nivolumab discontinued","author":"Park","journal-title":"Medical Professionals Reference"},{"key":"2026050905022527100_ref204","doi-asserted-by":"publisher","first-page":"e14507","DOI":"10.1200\/JCO.2023.41.16_suppl.e14507","article-title":"A phase 1\/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: Interim results. Abstract e14507","volume":"41","author":"Frentzas","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026050905022527100_ref205","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-SITC2022.1105","volume-title":"A Novel Triple Action and Pre-Clinical Safety Profile of SLC-3010 Predict its Favorable Translation in the Phase I Clinical Study. Abstract 1105","author":"Yoon","year":"2023"},{"key":"2026050905022527100_ref206","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT259","volume-title":"Results from Monotherapy Dose Escalation of MDNA11, a Long-Acting IL-2 Superkine, in a Phase 1\/2 Trial Show Evidence of Single-Agent Activity in Advanced Solid Tumors. Abstract CT259","author":"Atkinson","year":"2024"},{"key":"2026050905022527100_ref207","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1158\/2767-9764.CRC-24-0278","article-title":"A precision engineered Interleukin-2 for bolstering CD8+ T- and NK-cell activity without eosinophilia and vascular leak syndrome in nonhuman primates","volume":"4","author":"Ma","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2026050905022527100_ref208","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/cancers13040837","article-title":"Heterodimeric IL-15 in cancer immunotherapy","volume":"13","author":"Bergamaschi","year":"2021","journal-title":"Cancers"},{"key":"2026050905022527100_ref209","doi-asserted-by":"publisher","first-page":"e007725","DOI":"10.1136\/jitc-2023-007725","article-title":"First-in-human phase I\/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15R\u03b1, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors","volume":"11","author":"Leidner","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026050905022527100_ref210","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41587-022-01510-z","article-title":"A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy","volume":"41","author":"Quijano-Rubio","year":"2023","journal-title":"Nat Biotechnol"},{"key":"2026050905022527100_ref211","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1158\/2326-6066.CIR-22-0304","article-title":"NL-201 upregulates MHC-I expression and intratumoral T-cell receptor diversity, and demonstrates robust antitumor activity as monotherapy and in combination with PD-1 blockade","volume":"11","author":"Mortales","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"2026050905022527100_ref212","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2147\/DDDT.S493011","article-title":"SHR-1916: a novel PEGylated interleukin-2 analogue with altered cellular selectivity and improved pharmacokinetic profiles for cancer immunotherapy","volume":"19","author":"Kong","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"2026050905022527100_ref213","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3390\/pharmaceutics16091154","article-title":"Recent advances in drug delivery strategies for high-risk BCG-unresponsive non-muscle invasive bladder cancer: a brief review from 2018 to 2024","volume":"16","author":"Qu","year":"2024","journal-title":"Pharmaceutics"},{"key":"2026050905022527100_ref214","year":"2024"},{"key":"2026050905022527100_ref215","volume-title":"QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 (N-803) in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer","author":"NCT03022825"},{"key":"2026050905022527100_ref216","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3892\/ijmm.2019.4418","article-title":"Precision medicine for human cancers with notch signaling dysregulation (review)","volume":"45","author":"Katoh","year":"2020","journal-title":"Int J Mol Med"},{"key":"2026050905022527100_ref217","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41698-024-00739-y","article-title":"Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms","volume":"8","author":"Serrano","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026050905022527100_ref218","volume-title":"Neuroendocrine Tumors"},{"key":"2026050905022527100_ref219","doi-asserted-by":"publisher","first-page":"114248","DOI":"10.1016\/j.biopha.2023.114248","article-title":"Targeting the notch signaling pathway and the notch ligand, DLL3, in small cell lung cancer","volume":"159","author":"Zhang","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2026050905022527100_ref220","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12943-024-02012-z","article-title":"DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy","volume":"23","author":"Su","year":"2024","journal-title":"Mol Cancer"},{"key":"2026050905022527100_ref221","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2026050905022527100_ref222","doi-asserted-by":"publisher","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026050905022527100_ref223","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.jtho.2021.07.012","article-title":"All that glitters is not gold: the story of rovalpituzumab tesirine in SCLC","volume":"16","author":"Uprety","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026050905022527100_ref224","volume-title":"StatPearls [Internet]","author":"Basumallik","year":"2023"},{"key":"2026050905022527100_ref225","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","article-title":"A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026050905022527100_ref226","first-page":"62","article-title":"MT-103 micromet\/MedImmune","volume":"8","author":"Cheadle","year":"2006","journal-title":"Curr Opin Mol Ther"},{"key":"2026050905022527100_ref227","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.molimm.2006.09.032","article-title":"CD19-\/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis","volume":"44","author":"M\u00f8lh\u00f8j","year":"2007","journal-title":"Mol Immunol"},{"key":"2026050905022527100_ref228","author":"Amgen to acquire Micromet","year":"2012"},{"key":"2026050905022527100_ref229","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40265-015-0356-3","article-title":"Blinatumomab: first global approval","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"key":"2026050905022527100_ref230","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1074\/jbc.M116.748707","article-title":"Biological Characterization of a Stable Effector Functionless (SEFL) Monoclonal Antibody Scaffold in Vitro","volume":"292","author":"Liu","year":"2017","journal-title":"J Biol Chem"},{"key":"2026050905022527100_ref231","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/antib14010016","article-title":"Immune cell engagers: advancing precision immunotherapy for cancer treatment","volume":"14","author":"In","year":"2025","journal-title":"Antibodies (Basel)"},{"key":"2026050905022527100_ref232","volume-title":"A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC) (DeLLphi-301)","author":"NCT05060016"},{"key":"2026050905022527100_ref233","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"2026050905022527100_ref234","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1080\/14796694.2024.2402152","article-title":"Plain language summary: tarlatamab for patients with previously treated small cell lung cancer","volume":"20","author":"Ahn","year":"2024","journal-title":"Future Oncol"},{"key":"2026050905022527100_ref235","doi-asserted-by":"publisher","first-page":"1470595","DOI":"10.3389\/fphar.2024.1470595","article-title":"T-cell engagers: model interrogation as a tool to quantify the interplay of relative affinity and target expression on trimer formation","volume":"15","author":"Lai","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026050905022527100_ref236","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.24.00553","article-title":"Sustained clinical benefit and intracranial activity of tarlatamab in previously treated small cell lung cancer: DeLLphi-300 trial update","volume":"42","author":"Dowlati","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026050905022527100_ref237","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2478\/raon-2024-0027","article-title":"Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management","volume":"58","author":"Kovac","year":"2024","journal-title":"Radiol Oncol"},{"key":"2026050905022527100_ref238","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal Fc receptor (FcRn): a misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front Immunol"},{"key":"2026050905022527100_ref239","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s40262-024-01451-7","article-title":"Pharmacokinetics of tarlatamab, a delta-like ligand-3 (DLL3) targeted half-life extended bispecific T-cell engager (BiTE\u00ae) immunotherapy in adult patients with previously treated small-cell lung cancer: results from DeLLphi-300, a phase I multiple-dose-escalation study","volume":"63","author":"Minocha","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"2026050905022527100_ref240","author":"Blincyto\u00ae Prescribing information","year":"2024"},{"key":"2026050905022527100_ref241","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cca.2016.12.017","article-title":"Complement in autoimmune diseases","volume":"465","author":"Vignesh","year":"2017","journal-title":"Clin Chim Acta"},{"key":"2026050905022527100_ref242","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41422-023-00779-2","article-title":"Mechanism of activation and biased signaling in complement receptor C5aR1","volume":"33","author":"Feng","year":"2023","journal-title":"Cell Res"},{"key":"2026050905022527100_ref243","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1053\/j.seminhematol.2018.02.003","article-title":"Mechanisms of complement-mediated damage in hematological disorders","volume":"55","author":"Taylor","year":"2018","journal-title":"Semin Hematol"},{"key":"2026050905022527100_ref244","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.transci.2016.04.008","article-title":"The role of complement activation in thrombosis and hemolytic anemias","volume":"54","author":"Chapin","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"2026050905022527100_ref245","author":"Soliris\u00ae Prescribing information","year":"2007"},{"key":"2026050905022527100_ref246","author":"Ultomiris\u00ae Prescribing information","year":"2018"},{"key":"2026050905022527100_ref247","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s40265-023-01955-9","article-title":"Pozelimab: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"2026050905022527100_ref248","author":"Veopoz\u2122 Prescribing information","year":"2023"},{"key":"2026050905022527100_ref249","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1146\/annurev-immunol-032713-120154","article-title":"Complement and its receptors: new insights into human disease","volume":"32","author":"Holers","year":"2014","journal-title":"Ann Rev Immunol"},{"key":"2026050905022527100_ref250","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"key":"2026050905022527100_ref251","doi-asserted-by":"publisher","first-page":"11679","DOI":"10.3390\/ijms252111679","article-title":"Beyond recycling antibodies: crovalimab\u2019s molecular design enables four-weekly subcutaneous injections for PNH treatment","volume":"25","author":"Sampei","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026050905022527100_ref252","doi-asserted-by":"publisher","first-page":"e0231892","DOI":"10.1371\/journal.pone.0231892","article-title":"Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5","volume":"15","author":"Latuszek","year":"2020","journal-title":"PloS One"},{"key":"2026050905022527100_ref253","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/nbt.1691","article-title":"Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization","volume":"28","author":"Igawa","year":"2010","journal-title":"Nat Biotechnol"},{"key":"2026050905022527100_ref254","volume-title":"A Phase III Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated with Complement Inhibitors. (COMMODORE 2)","author":"NCT04434092"},{"key":"2026050905022527100_ref255","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/ajh.27412","article-title":"Phase 3 randomized COMMODORE 2 trial: crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition","volume":"99","author":"R\u00f6th","year":"2024","journal-title":"Am J Hematol"},{"key":"2026050905022527100_ref256","volume-title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated with Complement Inhibition (COMMODORE 3)","author":"NCT04654468"},{"key":"2026050905022527100_ref257","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/ajh.26998","article-title":"Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): a multicenter, phase 3, single-arm study","volume":"98","author":"Liu","year":"2023","journal-title":"Am J Hematol"},{"key":"2026050905022527100_ref258","doi-asserted-by":"publisher","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PloS One"},{"key":"2026050905022527100_ref259","doi-asserted-by":"publisher","first-page":"1020580","DOI":"10.3389\/fimmu.2022.1020580","article-title":"Inhibition of the different complement pathways has varying impacts on the serum bactericidal activity and opsonophagocytosis against Haemophilus influenzae type b","volume":"13","author":"Muri","year":"2022","journal-title":"Front Immunol"},{"key":"2026050905022527100_ref260","author":"Alzheimer\u2019s Association","year":"2024"},{"key":"2026050905022527100_ref261","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/biomedicines9091126","article-title":"Alzheimer's disease: a molecular view of \u03b2-amyloid induced morbific events","volume":"9","author":"Mohamed Asik","year":"2021","journal-title":"Biomedicines"},{"key":"2026050905022527100_ref262","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fnins.2018.00025","article-title":"Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer's disease","volume":"12","author":"Kametani","year":"2018","journal-title":"Front Neurosci"},{"key":"2026050905022527100_ref263","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fncel.2015.00138","article-title":"Additional mechanisms conferring genetic susceptibility to Alzheimer's disease","volume":"9","author":"Calero","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"2026050905022527100_ref264","doi-asserted-by":"publisher","first-page":"658","DOI":"10.4103\/1673-5374.247469","article-title":"Mutations of beta-amyloid precursor protein alter the consequence of Alzheimer's disease pathogenesis","volume":"14","author":"Li","year":"2019","journal-title":"Neural Regen Res"},{"key":"2026050905022527100_ref265","doi-asserted-by":"publisher","first-page":"041003","DOI":"10.1115\/1.4067701","article-title":"Evaluating the combined neurotoxicity of amyloid beta and tau oligomers in Alzheimer's disease: a novel cellular-level criterion","volume":"147","author":"Kuznetsov","year":"2025","journal-title":"J Biomech Eng"},{"key":"2026050905022527100_ref266","doi-asserted-by":"publisher","first-page":"105754","DOI":"10.1016\/j.phrs.2021.105754","article-title":"Aducanumab for Alzheimer's disease: a regulatory perspective","volume":"171","author":"Nistic\u00f2","year":"2021","journal-title":"Pharmacol Res"},{"key":"2026050905022527100_ref267","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3233\/ADR-230025","article-title":"Antibody-mediated clearance of brain amyloid-\u03b2: mechanisms of action, effects of natural and monoclonal anti-a\u03b2 antibodies, and downstream effects","volume":"7","author":"Loeffler","year":"2023","journal-title":"J Alzheimers Dis Rep"},{"key":"2026050905022527100_ref268","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","article-title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2","volume":"8","author":"Arndt","year":"2018","journal-title":"Sci Rep"},{"key":"2026050905022527100_ref269","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-med-051022-043645","article-title":"Lessons learned from approval of aducanumab for Alzheimer's disease","volume":"75","author":"Heidebrink","year":"2024","journal-title":"Annu Rev Med"},{"key":"2026050905022527100_ref270","doi-asserted-by":"publisher","first-page":"q281","DOI":"10.1136\/bmj.q281","article-title":"Aduhelm: Biogen abandons Alzheimer's drug after controversial approval left it unfunded by Medicare","volume":"384","author":"Dyer","year":"2024","journal-title":"BMJ."},{"key":"2026050905022527100_ref271","doi-asserted-by":"publisher","first-page":"128","DOI":"10.48101\/ujms.v128.10316","article-title":"A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease","volume":"128","author":"Lannfelt","year":"2023","journal-title":"Ups J Med Sci"},{"key":"2026050905022527100_ref272","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"key":"2026050905022527100_ref273","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JAD-240189","article-title":"Amyloid-directed antibodies: past, present, and future","volume":"101","author":"Noorda","year":"2024","journal-title":"J Alzheimers Dis"},{"key":"2026050905022527100_ref274","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1038\/s41380-021-01409-2","article-title":"Pyroglutamate a\u03b2 cascade as drug target in Alzheimer's disease","volume":"27","author":"Bayer","year":"2022","journal-title":"Mol Psychiatry"},{"key":"2026050905022527100_ref275","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s40265-024-02103-7","article-title":"Donanemab: first approval","volume":"84","author":"Kang","year":"2024","journal-title":"Drugs"},{"key":"2026050905022527100_ref276","doi-asserted-by":"publisher","first-page":"100088","DOI":"10.1016\/j.tjpad.2025.100088","article-title":"Eligibility for donanemab trial in a population-based study of cognitive aging","volume":"12","author":"Jones","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"2026050905022527100_ref277","volume-title":"A Study of Donanemab (LY3002813) in Participants with Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)","author":"NCT04437511"},{"key":"2026050905022527100_ref278","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA."},{"key":"2026050905022527100_ref279","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/pharmacy13010023","article-title":"Targeting amyloid pathology in early Alzheimer's: the promise of donanemab-azbt","volume":"13","author":"Khartabil","year":"2025","journal-title":"Pharmacy (Basel)"},{"key":"2026050905022527100_ref280","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s40120-024-00649-y","article-title":"Estimating the economically justifiable price of limited-duration treatment with donanemab for early symptomatic Alzheimer's disease in the United States","volume":"13","author":"Boustani","year":"2024","journal-title":"Neurol Ther"},{"key":"2026050905022527100_ref281","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026050905022527100_ref282","volume-title":"Eli Lilly\u2019s Remternetug Demonstrates Significant Amyloid Plaque Removal in Early-Stage Trial","author":"Meglio","year":"2023"},{"key":"2026050905022527100_ref283","volume-title":"A Study of Remternetug (LY3372993) in Participants with Alzheimer's Disease (TRAILRUNNER-ALZ 1)","author":"NCT05463731"},{"key":"2026050905022527100_ref284"},{"key":"2026050905022527100_ref285","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/ijd.17707","article-title":"Type 2 inflammation and its role in dermatologic diseases","volume":"64","author":"Chovatiya","year":"2025","journal-title":"Int J Dermatol"},{"key":"2026050905022527100_ref286","author":"Eczema stats"},{"key":"2026050905022527100_ref287","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jdin.2023.12.013","article-title":"Prevalence of prurigo nodularis in the United States","volume":"18","author":"Kwatra","year":"2024","journal-title":"JAAD Int"},{"key":"2026050905022527100_ref288","doi-asserted-by":"publisher","first-page":"43","DOI":"10.14789\/ejmj.JMJ24-0036-R","article-title":"Mechanisms of itch in atopic dermatitis","volume":"71","author":"Kamata","year":"2025","journal-title":"Juntendo Med J"},{"key":"2026050905022527100_ref289","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1177\/039463201002300304","article-title":"IL-31 a Th2 cytokine involved in immunity and inflammation","volume":"23","author":"Castellani","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2026050905022527100_ref290","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol"},{"key":"2026050905022527100_ref291"},{"key":"2026050905022527100_ref292","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jaci.2023.04.019","article-title":"Single-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis","volume":"152","author":"Alkon","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2026050905022527100_ref293","doi-asserted-by":"publisher","first-page":"639097","DOI":"10.3389\/fmed.2021.639097","article-title":"Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues","volume":"8","author":"Nemmer","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026050905022527100_ref294","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/exd.14279","article-title":"Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta","volume":"30","author":"Hashimoto","year":"2021","journal-title":"Exp Dermatol"},{"key":"2026050905022527100_ref295","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"2026050905022527100_ref296","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1111\/all.14791","article-title":"Interleukin-31: the \u201citchy\u201d cytokine in inflammation and therapy","volume":"76","author":"Datsi","year":"2021","journal-title":"Allergy."},{"key":"2026050905022527100_ref297","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/exd.13533","article-title":"Interleukin-31 and interleukin-31 receptor: new therapeutic targets for atopic dermatitis","volume":"27","author":"Nakashima","year":"2018","journal-title":"Exp Dermatol"},{"key":"2026050905022527100_ref298","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14207","article-title":"The first trial of CIM331, a humanized anti-human interleukin-31 receptor a antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br J Dermatol"},{"key":"2026050905022527100_ref299","author":"Galderma Receives U.S","year":"2024"},{"key":"2026050905022527100_ref300","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40265-022-01741-z","article-title":"Nemolizumab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"2026050905022527100_ref301","volume-title":"Galderma\u2019s Nemluvio\u00ae (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis","year":"2025"},{"key":"2026050905022527100_ref302","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ymeth.2013.06.035","article-title":"An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations","volume":"65","author":"Vafa","year":"2014","journal-title":"Methods"},{"key":"2026050905022527100_ref303","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R","volume":"276","author":"Shields","year":"2001","journal-title":"J Biol Chem"},{"key":"2026050905022527100_ref304","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/eji.200324733","article-title":"Functional mapping of the Fc gamma RII binding site on human IgG1 by synthetic peptides","volume":"34","author":"Medgyesi","year":"2004","journal-title":"Eur J Immunol"},{"key":"2026050905022527100_ref305","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fc gamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"2026050905022527100_ref306","author":"Kancko"},{"key":"2026050905022527100_ref307","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","article-title":"Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase 3 trial","volume":"161","author":"St\u00e4nder","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2026050905022527100_ref308","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N Engl J Med"},{"key":"2026050905022527100_ref309","doi-asserted-by":"publisher","first-page":"851940","DOI":"10.3389\/fphar.2022.851940","article-title":"Interleukins 4 and 13 in asthma: key pathophysiologic cytokines and druggable molecular targets","volume":"13","author":"Pelaia","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026050905022527100_ref310","doi-asserted-by":"publisher","first-page":"3000605241286832","DOI":"10.1177\/03000605241286832","article-title":"IL-13 inhibition in the treatment of atopic dermatitis - new and emerging biologic agents","volume":"52","author":"Teixeira","year":"2024","journal-title":"J Int Med Res"},{"key":"2026050905022527100_ref311","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front Immunol"},{"key":"2026050905022527100_ref312","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.cell.2007.12.030","article-title":"Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4\/13 system","volume":"132","author":"LaPorte","year":"2008","journal-title":"Cell"},{"key":"2026050905022527100_ref313","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.str.2010.01.003","article-title":"Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2","volume":"18","author":"Lupardus","year":"2010","journal-title":"Structure"},{"key":"2026050905022527100_ref314","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cyto.2015.05.023","article-title":"Commentary: IL-4 and IL-13 receptors and signaling","volume":"75","author":"McCormick","year":"2015","journal-title":"Cytokine"},{"key":"2026050905022527100_ref315","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.jmb.2013.01.024","article-title":"Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab","volume":"425","author":"Ultsch","year":"2013","journal-title":"J Mol Biol"},{"key":"2026050905022527100_ref316","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s13555-023-00947-7","article-title":"Binding, neutralization and internalization of the interleukin-13 antibody, lebrikizumab","volume":"13","author":"Okragly","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026050905022527100_ref317","volume-title":"Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)","author":"NCT04146363"},{"key":"2026050905022527100_ref318","volume-title":"Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2)","author":"NCT04178967"},{"key":"2026050905022527100_ref319","volume-title":"Safety and Efficacy of Lebrikizumab (LY3650150) in Combination with Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. (ADhere)","author":"NCT04250337"},{"key":"2026050905022527100_ref320","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12325-024-02974-y","article-title":"Improvement across dimensions of disease with lebrikizumab use in atopic dermatitis: two phase 3, randomized, double-blind, placebo-controlled monotherapy trials (ADvocate1 and ADvocate2)","volume":"42","author":"Simpson","year":"2025","journal-title":"Adv Ther"},{"key":"2026050905022527100_ref321","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","article-title":"Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling","volume":"119","author":"Hume","year":"2012","journal-title":"Blood"},{"key":"2026050905022527100_ref322","doi-asserted-by":"publisher","first-page":"a021857","DOI":"10.1101\/cshperspect.a021857","article-title":"CSF-1 receptor signaling in myeloid cells","volume":"6","author":"Stanley","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2026050905022527100_ref323","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.str.2012.02.010","article-title":"Structural basis for the dual recognition of helical cytokines IL-34 and CSF-1 by CSF-1R","volume":"20","author":"Ma","year":"2012","journal-title":"Structure"},{"key":"2026050905022527100_ref324","doi-asserted-by":"publisher","first-page":"156348","DOI":"10.1016\/j.cyto.2023.156348","article-title":"Role of IL-34 and its receptors in inflammatory diseases","volume":"171","author":"Shang","year":"2023","journal-title":"Cytokine"},{"key":"2026050905022527100_ref325","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/abt\/tbaa018","article-title":"A blocking antibody against canine CSF-1R maturated by limited CDR mutagenesis","volume":"3","author":"Beir\u00e3o","year":"2020","journal-title":"Antib Ther"},{"key":"2026050905022527100_ref326","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3390\/cells13181524","article-title":"Current approaches for the prevention and treatment of acute and chronic GVHD","volume":"13","author":"Olivieri","year":"2024","journal-title":"Cells."},{"key":"2026050905022527100_ref327","first-page":"P402","article-title":"Targeting colony stimulating factor- 1 receptor (CSF-1R) with SNDX-6352, a novel anti-CSF-1R targeted antibody","volume":"4","author":"Ordentlich","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2026050905022527100_ref328","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.22.00958","article-title":"Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study","volume":"41","author":"Kitko","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026050905022527100_ref329","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"Axatilimab in recurrent or refractory chronic graft-versus-host disease","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"},{"key":"2026050905022527100_ref330","doi-asserted-by":"publisher","first-page":"102160","DOI":"10.1016\/j.rpth.2023.102160","article-title":"New insight into the traditional model of the coagulation cascade and its regulation: illustrated review of a three-dimensional view","volume":"7","author":"Troisi","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"2026050905022527100_ref331","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1161\/ATVBAHA.118.312130","article-title":"Intrinsic pathway of coagulation and thrombosis","volume":"39","author":"Grover","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026050905022527100_ref332","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026050905022527100_ref333","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/ATVBAHA.107.141911","article-title":"Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis","volume":"27","author":"Mackman","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026050905022527100_ref334","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1161\/ATVBAHA.107.141606","article-title":"The haemostatic role of tissue factor pathway inhibitor","volume":"28","author":"Crawley","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026050905022527100_ref335","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/jth.15697","article-title":"Regulation of coagulation by tissue factor pathway inhibitor: implications for hemophilia therapy","volume":"20","author":"Mast","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2026050905022527100_ref336","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia a and B: molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica."},{"key":"2026050905022527100_ref337","volume-title":"StatPearls [Internet]","author":"Salen","year":"2025"},{"key":"2026050905022527100_ref338","author":"National Hemophilia Foundation"},{"key":"2026050905022527100_ref339","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/10245330600921964","article-title":"Inherited factor XI deficiency: a concise review","volume":"11","author":"Franchini","year":"2006","journal-title":"Hematology."},{"key":"2026050905022527100_ref340","volume-title":"StatPearls [Internet]","author":"Haider","year":"2025"},{"key":"2026050905022527100_ref341","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1182\/asheducation-2016.1.657","article-title":"Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches","volume":"2016","author":"Meeks","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2026050905022527100_ref342","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/hematology.2021000253","article-title":"Factor-mimetic and rebalancing therapies in hemophilia a and B: the end of factor concentrates?","volume":"2021","author":"Ellsworth","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2026050905022527100_ref343","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/hae.14167","article-title":"Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors","volume":"27","author":"Jim\u00e9nez-Yuste","year":"2021","journal-title":"Haemophilia."},{"key":"2026050905022527100_ref344","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40265-018-0861-2","article-title":"Emicizumab-kxwh: first global approval","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs."},{"key":"2026050905022527100_ref345","author":"Hympavzi\u00ae (marstasimab-hncq)"},{"key":"2026050905022527100_ref346","author":"Comparing Alhemo\u00ae vs Hympavzi\u00ae"},{"key":"2026050905022527100_ref347","author":"Hemlibra\u00ae prescribing information","year":"2023"},{"key":"2026050905022527100_ref348","author":"Hemlibra\u00ae prices, coupons, copay cards & patient assistance"},{"key":"2026050905022527100_ref349","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/d41573-024-00175-4","article-title":"FDA approves first anti-TFPI antibody for haemophilia A and B","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2026050905022527100_ref350","volume-title":"Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B","author":"NCT03938792"},{"key":"2026050905022527100_ref351","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40265-023-01912-6","article-title":"Concizumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"2026050905022527100_ref352","volume-title":"Research Study to Look at how Well the Drug Concizumab Works in your Body if you Have Haemophilia with Inhibitors (explorer7)","author":"NCT04083781"},{"key":"2026050905022527100_ref353","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"key":"2026050905022527100_ref354","volume-title":"Research Study to Look at how Well the Drug Concizumab Works in Your Body if you Have Haemophilia without Inhibitors (explorer8)","author":"NCT04082429"},{"key":"2026050905022527100_ref355","doi-asserted-by":"publisher","first-page":"e891","DOI":"10.1016\/S2352-3026(24)00307-7","article-title":"Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial","volume":"11","author":"Chowdary","year":"2024","journal-title":"Lancet Haematol"},{"key":"2026050905022527100_ref356","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.3390\/ijms25094634","article-title":"Claudins in cancer: a current and future therapeutic target","volume":"25","author":"Hana","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026050905022527100_ref357","doi-asserted-by":"publisher","first-page":"541957","DOI":"10.1155\/2010\/541957","article-title":"Claudin family of proteins and cancer: An overview","volume":"2010","author":"Singh","year":"2010","journal-title":"J Oncol"},{"key":"2026050905022527100_ref358","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1186\/s12885-025-13940-4","article-title":"Claudin 18.2 expression profile in primary tumors and their ovarian metastases: implications for targeted therapy","volume":"25","author":"Kim","year":"2025","journal-title":"BMC Cancer"},{"key":"2026050905022527100_ref359","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3892\/ijmm.2024.5424","article-title":"Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (review)","volume":"54","author":"Katoh","year":"2024","journal-title":"Int J Mol Med"},{"key":"2026050905022527100_ref360","author":"Jeremias","year":"2025"},{"key":"2026050905022527100_ref361","volume-title":"StatPearls [Internet]","author":"Menon","year":"2025"},{"key":"2026050905022527100_ref370","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41598-017-18892-9","article-title":"The effects of antibody engineering CH and CL in trastuzumab and pertuzumab recombinant models: impact on antibody production and antigen-binding","volume":"8","author":"Lua","year":"2018","journal-title":"Sci Rep"},{"key":"2026050905022527100_ref371","author":"Herceptin\u00ae prescribing information","year":"2024"},{"key":"2026050905022527100_ref372","doi-asserted-by":"publisher","first-page":"7837","DOI":"10.1007\/s00216-018-1414-y","article-title":"Affinity profiling of monoclonal antibody and antibody-drug-conjugate preparations by coupled liquid chromatography-surface plasmon resonance biosensing","volume":"410","author":"Lakayan","year":"2018","journal-title":"Anal Bioanal Chem"},{"key":"2026050905022527100_ref373","author":"Perjeta\u00ae prescribing information","year":"2024"},{"key":"2026050905022527100_ref374","author":"Kadcyla\u00ae prescribing information","year":"2024"},{"key":"2026050905022527100_ref375","author":"Enhertu\u00ae prescribing information","year":"2024"},{"key":"2026050905022527100_ref376","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026050905022527100_ref377","author":"Margenza\u00ae prescribing information","year":"2024"},{"key":"2026050905022527100_ref378","doi-asserted-by":"publisher","first-page":"8882","DOI":"10.1158\/0008-5472.CAN-07-0696","article-title":"Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fc-gamma receptors","volume":"67","author":"Stavenhagen","year":"2007","journal-title":"Cancer Res"},{"key":"2026050905022527100_ref379","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/bcr3069","article-title":"Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc\u03b3 receptor binding properties","volume":"13","author":"Nordstrom","year":"2011","journal-title":"Breast Cancer Res"},{"key":"2026050905022527100_ref380","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","article-title":"An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity","volume":"14","author":"Weisser","year":"2023","journal-title":"Nat Commun"},{"key":"2026050905022527100_ref381","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.ccell.2018.04.003","article-title":"Unbiased combinatorial screening identifies a bispecific IgG1 that potently inhibits HER3 Signaling via HER2-guided ligand blockade","volume":"33","author":"Geuijen","year":"2018","journal-title":"Cancer Cell"},{"key":"2026050905022527100_ref382","doi-asserted-by":"publisher","first-page":"14706","DOI":"10.1074\/jbc.M117.793497","article-title":"A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1","volume":"292","author":"De Nardis","year":"2017","journal-title":"J Biol Chem"},{"key":"2026050905022527100_ref383","doi-asserted-by":"publisher","first-page":"12031","DOI":"10.3390\/ijms241512031","article-title":"Binding affinity of trastuzumab and pertuzumab monoclonal antibodies to extracellular HER2 domain","volume":"24","author":"Cruz","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026050905022527100_ref362","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/d41573-024-00172-7","article-title":"FDA approves first claudin-18.2-targeted antibody for gastric cancer","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2026050905022527100_ref363","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/17460441.2024.2370332","article-title":"The preclinical discovery and development of zolbetuximab for the treatment of gastric cancer","volume":"19","author":"Zeng","year":"2024","journal-title":"Expert Opin Drug Discovery"},{"key":"2026050905022527100_ref364","doi-asserted-by":"publisher","first-page":"472","DOI":"10.46883\/2024.25921031","article-title":"Efficacy and safety of zolbetuximab in gastric cancer","volume":"38","author":"Waheed","year":"2024","journal-title":"Oncology (Williston Park)"},{"key":"2026050905022527100_ref365","volume-title":"A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)","author":"NCT03504397"},{"key":"2026050905022527100_ref366","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1080\/14796694.2024.2342107","article-title":"Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary","volume":"20","author":"Shitara","year":"2024","journal-title":"Future Oncol"},{"key":"2026050905022527100_ref367","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","article-title":"Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Shitara","year":"2024","journal-title":"Gastric Cancer"},{"key":"2026050905022527100_ref368","volume-title":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-Line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)","author":"NCT03653507"},{"key":"2026050905022527100_ref369","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJMc2409512","article-title":"Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma","volume":"391","author":"Shitara","year":"2024","journal-title":"N Engl J Med"},{"key":"2026050905022527100_ref384","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"2026050905022527100_ref385","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/antib10010007","article-title":"Trastuzumab blocks the receiver function of HER2 leading to the population shifts of HER2-containing homodimers and heterodimers","volume":"10","author":"Zhao","year":"2021","journal-title":"Antibodies (Basel)"},{"key":"2026050905022527100_ref386","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ebiom.2015.02.005","article-title":"Clinical translation and validation of a predictive biomarker for patritumab, an anti-human epidermal growth factor receptor 3 (HER3) monoclonal antibody, in patients with advanced non-small cell lung cancer","volume":"2","author":"Mendell","year":"2015","journal-title":"EBioMedicine."},{"key":"2026050905022527100_ref387","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41571-025-01008-y","article-title":"Emerging importance of HER3 in tumorigenesis and cancer therapy","volume":"22","author":"Garrett","year":"2025","journal-title":"Nat Rev Clin Oncol."},{"key":"2026050905022527100_ref388","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/cancers11030375","article-title":"The effects of pertuzumab and its combination with trastuzumab on HER2 homodimerization and phosphorylation","volume":"11","author":"Nami","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026050905022527100_ref393","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s13046-022-02515-x","article-title":"HER3 in cancer: from the bench to the bedside","volume":"41","author":"Gandullo-S\u00e1nchez","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2026050905022527100_ref389","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/319226a0","article-title":"The neu oncogene encodes an epidermal growth factor receptor-related protein","volume":"319","author":"Bargmann","year":"1986","journal-title":"Nature"},{"key":"2026050905022527100_ref390","first-page":"423","article-title":"Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis","volume":"1","author":"Varley","year":"1987","journal-title":"Oncogene"},{"key":"2026050905022527100_ref391","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"2026050905022527100_ref392","first-page":"1727","article-title":"Monoclonal antibody approved for metastatic breast cancer","volume":"12","author":"No author listed","year":"1998","journal-title":"Oncology (Williston Park)"},{"key":"2026050905022527100_ref394","doi-asserted-by":"publisher","first-page":"14","DOI":"10.21037\/cco-22-93","article-title":"Targeted therapies in advanced biliary tract cancers-a narrative review","volume":"12","author":"LaPelusa","year":"2023","journal-title":"Chin Clin Oncol"},{"key":"2026050905022527100_ref395","year":"2022"},{"key":"2026050905022527100_ref396","volume-title":"A Study of ZW25 (Zanidatamab) in Subjects with Advanced or Metastatic HER2-Amplified Biliary Tract Cancers (HERIZON-BTC-01)","author":"NCT04466891"},{"key":"2026050905022527100_ref397","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026050905022527100_ref398","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1080\/14796694.2024.2368952","article-title":"A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer","volume":"20","author":"Harding","year":"2024","journal-title":"Future Oncol"},{"key":"2026050905022527100_ref399","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","article-title":"Zenocutuzumab, a HER2 x HER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements","volume":"12","author":"Schram","year":"2022","journal-title":"Cancer Discov"},{"key":"2026050905022527100_ref400","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/2159-8290.CD-18-0036","article-title":"NRG1 fusions in KRAS wild-type pancreatic cancer","volume":"8","author":"Heining","year":"2018","journal-title":"Cancer Discov"},{"key":"2026050905022527100_ref401","doi-asserted-by":"publisher","first-page":"103465","DOI":"10.1016\/j.critrevonc.2021.103465","article-title":"The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer","volume":"166","author":"Umemoto","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026050905022527100_ref402","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/14728222.2021.1999927","article-title":"NRG1 and NRG2 fusions in non-small cell lung cancer (NSCLC): seven years between lights and shadows","volume":"25","author":"Trombetta","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"2026050905022527100_ref403","doi-asserted-by":"publisher","first-page":"1405380","DOI":"10.3389\/fonc.2024.1405380","article-title":"Analysis on the pathogenesis and treatment progress of NRG1 fusion-positive non-small cell lung cancer","volume":"14","author":"Li","year":"2024","journal-title":"Front Oncol"},{"key":"2026050905022527100_ref404","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/gcc.22942","article-title":"Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database","volume":"60","author":"Pt\u00e1kov\u00e1","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"2026050905022527100_ref405","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.annonc.2020.08.2335","article-title":"NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents","volume":"31","author":"Laskin","year":"2020","journal-title":"Ann Oncol"},{"key":"2026050905022527100_ref406","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.trecan.2021.11.003","article-title":"NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis","volume":"8","author":"Nagasaka","year":"2022","journal-title":"Trends Cancer"},{"key":"2026050905022527100_ref407","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s11912-025-01640-y","article-title":"NRG1 fusions: the new kid on the block","volume":"27","author":"Gupta","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"2026050905022527100_ref408","volume-title":"Mechanism of Action of MCLA-128, a Humanized Bispecific IgG1 Antibody Targeting the HER2:HER3 Heterodimer","author":"Geuijen","year":"2015"},{"key":"2026050905022527100_ref410","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion-positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"key":"2026050905022527100_ref411","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3892\/ol.2020.11583","article-title":"Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: molecular pathways and disease treatments","volume":"20","author":"Huang","year":"2020","journal-title":"Oncol Lett"},{"key":"2026050905022527100_ref412"},{"key":"2026050905022527100_ref423","doi-asserted-by":"publisher","first-page":"2285277","DOI":"10.1080\/19420862.2023.2285277","article-title":"Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume","volume":"15","author":"Desai","year":"2023","journal-title":"MAbs."},{"key":"2026050905022527100_ref426","author":"Rituxan Hycela\u00ae prescribing information"},{"key":"2026050905022527100_ref427","author":"Herceptin Hylecta\u00ae prescribing information"},{"key":"2026050905022527100_ref428","author":"Darzalex Faspro\u00ae prescribing information"},{"key":"2026050905022527100_ref429","author":"Phesgo\u00ae prescribing information"},{"key":"2026050905022527100_ref430","author":"Vyvgart Hytrulo\u00ae prescribing information"},{"key":"2026050905022527100_ref431","author":"Tecentriq Hybreza\u00ae prescribing information","year":"2024"},{"key":"2026050905022527100_ref432","author":"Ocrevus Zunovo\u00ae prescribing information","year":"2024"},{"key":"2026050905022527100_ref433","author":"Opdivo Qvantig\u00ae prescribing information","year":"2024"},{"key":"2026050905022527100_ref413","year":"2024"},{"key":"2026050905022527100_ref414","first-page":"180","volume-title":"WHO Drug Info","author":"Obecabtagenum autoleucelum","year":"2021"},{"key":"2026050905022527100_ref415","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"key":"2026050905022527100_ref416","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1200\/JCO.21.00917","article-title":"Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"39","author":"Roddie","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026050905022527100_ref417","author":"Autolus full year","year":"2023"},{"key":"2026050905022527100_ref418","volume-title":"A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)","author":"NCT04404660"},{"key":"2026050905022527100_ref419","author":"Aucatzyl\u00ae prescription information"},{"key":"2026050905022527100_ref420","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"key":"2026050905022527100_ref421","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/10717544.2018.1551442","article-title":"ENHANZE\u00ae drug delivery technology: A novel approach to subcutaneous administration using recombinant human hyaluronidase PH20","volume":"26","author":"Locke","year":"2019","journal-title":"Drug Deliv"},{"key":"2026050905022527100_ref422","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.matbio.2019.02.002","article-title":"Hyaluronan biology: a complex balancing act of structure, function, location and context","volume":"78-79","author":"Garantziotis","year":"2019","journal-title":"Matrix Biol"},{"key":"2026050905022527100_ref424","doi-asserted-by":"publisher","first-page":"885888","DOI":"10.3389\/fbioe.2022.885888","article-title":"Active expression of human hyaluronidase PH20 and characterization of its hydrolysis pattern","volume":"10","author":"Pang","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"2026050905022527100_ref425","author":"Hyqvia\u00ae prescribing information"},{"key":"2026050905022527100_ref434","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/bph.17458","article-title":"Novel drugs approved by the EMA, the FDA and the MHRA in 2024: a year in review","volume":"182","author":"Topouzis","year":"2025","journal-title":"Br J Pharmacol"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbaf014\/63606827\/tbaf014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/8\/3\/197\/63606827\/tbaf014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/8\/3\/197\/63606827\/tbaf014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T09:02:45Z","timestamp":1778317365000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/8\/3\/197\/8176596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":431,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6,12]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbaf014","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,6,12]]}}}